Inventiva reports 2025 Third Quarter Financial Information¹

Core Viewpoint - Inventiva, a clinical-stage biopharmaceutical company, reported its financial results for the first nine months of 2025, highlighting its cash position, revenue generation, and operational expenditures, while also discussing future financing and operational sustainability [1]. Financial Position - As of September 30, 2025, the company's cash and cash equivalents were €97.6 million, a slight increase from €96.6 million at the end of 2024 [2]. - The company also held €24.7 million in short-term deposits as of the same date [10]. Cash Flow Analysis - Net cash used in operating activities for the first nine months of 2025 was (€76.3) million, a 20% increase from (€63.7) million in the same period of 2024, attributed to working capital changes and the impact of a pipeline prioritization plan [3]. - Net cash used in investing activities was (€25.0) million, a significant decrease from €8.9 million generated in the same period of 2024, primarily due to variations in short-term deposits [4]. - Net cash generated from financing activities amounted to €103.4 million, up from €41.9 million in the same period of 2024, mainly from a structured financing settlement [5]. Revenue Generation - Revenues for the first nine months of 2025 totaled €4.5 million, compared to no revenue in the same period of 2024 [9]. - The revenue primarily consisted of a €10 million milestone payment from Chia Tai Tianqing Pharmaceutical Group and €4.3 million from credit notes under a license agreement [11]. Future Outlook - The company estimates that its current cash position, along with net proceeds from a recent public offering, will sustain operations until the end of the first quarter of 2027 [8]. - The company anticipates potential additional proceeds from the exercise of Tranche 3 warrants, which could extend its financial runway until mid-third quarter of 2027 [8]. Upcoming Events - Key upcoming milestones include topline results of the NATiV3 trial expected in the second half of 2026 [12]. - A combined general meeting of shareholders is scheduled for November 27, 2025 [13]. - Participation in the MASH-TAG scientific conference is set for January 7-11, 2026 [14].